Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly Playing Catch Up In Oncology

Executive Summary

The big pharma is chasing the competition in multiple areas of oncology, bringing forward offerings in CDK 4/6, as well as PD-L1.

You may also be interested in...



Lilly Teams Up With Boehringer Ingelheim To Boost Abemaciclib

The two big pharmas are working together in oncology in an effort to advance combination therapies in both their growing, but young oncology pipelines.

Ten Programs To Watch Out For At ASCO

The ASCO abstracts are out – and with them a scramble to see exactly what will be hitting the headlines in early June. Here, with the help of Sagient's BioMedTracker, Scrip takes a look at some of the more interesting studies due to be presented in Chicago in a couple weeks.

ASCO Puts A Spotlight On CDK4/6 Category Ahead Of New Competition

Data to be presented at the American Society of Oncology meeting in June on cyclin-dependent kinase 4/6 inhibitors, an important new category of drugs to treat breast cancer, suggest Pfizer Inc. is well positioned to maintain its lead in the category even as new competition prepares to enter the market.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC065279

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel